An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Interferon alpha
- Indications Malignant melanoma
- Focus Therapeutic Use
- 17 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2022.
- 17 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2021.
- 17 Apr 2018 Status changed from recruiting to active, no longer recruiting.